Investment Bridge, one of Japan's leading IR services companies, has released a “Bridge Report” on EIKEN CHEMICAL CO., LTD. (TOKYO: 4549) reviewing first half fiscal year March 2014 earnings results and full fiscal year March 2014 earnings estimates. Report Highlights * EIKEN CHEMICAL is a general manufacturer of clinical diagnostics, including immunological and serological, microbiological, clinical chemistry, urine analysis and molecular genetics. * Net sales of the first half of fiscal year (FY) 2014 was 15,000 million yen, up 2.9% year-on-year. * There is no change in the estimates for FY 2014. * Overall sales exceeded the sales and profit estimates announced at the beginning of the fiscal year, and the business performance shows steady improvement. EIKEN CHEMICAL is the major manufacturer of clinical diagnostics. Its immunochemical fecal occult blood test reagents occupies over 50% share of the domestic market. It is strengthening its molecular genetics. It is actively promoting license business. About Bridge Report: Bridge Report is produced by Investment Bridge Co., Ltd. and provides accurate and objective information about the earnings, business strategies, and other information of publicly traded Japanese companies. Contact: Investment Bridge Co., Ltd. mailto:email@example.com Contributed via: Bloomberg Publisher WEB Service
Bridge Report on EIKEN CHEMICAL CO., LTD. Issued: 1H FY3/14 Results and Full FY3/14 Estimates
Press spacebar to pause and continue. Press esc to stop.